Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

Doral FDA Compliance Attorney

This guide explains how FDA compliance matters work for businesses in Doral — the rules, the deadlines, the process and the mistakes — and how Garg Law handles them. Doral is where Miami’s trade industry keeps its headquarters — thousands of import, export, logistics and distribution firms operate from its office parks and warehouses west of Miami International Airport. From family-run food importers to hemisphere-wide distribution arms of global brands, Doral companies clear FDA-regulated merchandise through MIA and PortMiami every business day.

Quick answer

FDA compliance is a lifecycle discipline: classification, registrations and listings, labeling and claims, manufacturing controls, import requirements, and the enforcement that follows when any of them slip. Counsel that works across every FDA-regulated product category — foods, supplements, cosmetics, OTC drugs, devices — catches the cross-cutting problems single-category advisors miss.

1. Overview: the regulatory framework

FDA regulates most of what Miami imports and sells: foods and beverages, dietary supplements, cosmetics, over-the-counter drugs, medical devices, and more. Each category carries its own regime — FSMA’s preventive controls and supplier verification for food, MoCRA for cosmetics, the monograph system for OTC drugs, registration and listing for devices — but a company’s risk runs across all of them at once.

The recurring compliance questions are classification (is this product a food, supplement, cosmetic or drug — often decided by its claims), registration and listing obligations, labeling and advertising review, manufacturing and supplier controls, and import compliance for everything sourced abroad. Getting classification wrong contaminates every downstream decision.

Enforcement is the other half: FDA inspections and Form 483 responses, warning letters, recalls, import actions and, for serious matters, injunctions and seizures. Companies that treat a warning letter as a template exercise learn how quickly FDA escalates; companies with counsel respond in the agency’s language, with corrective actions FDA credits.

2. What is at stake

FDA problems compound quietly and surface expensively — a misclassified product line, an unregistered facility or an unsupportable claim can invalidate inventory, freeze imports and draw enforcement that reaches company principals. The cost curve strongly favors compliance built before FDA is asking the questions.

3. Step-by-step: how the matter proceeds

  1. Regulatory assessment across your product portfolio: classification, applicable regimes, and current-state gaps
  2. Registration, listing and facility-obligation audit — what FDA thinks it knows about you versus reality
  3. Labeling and claims review before printing and campaigns, not after a warning letter
  4. Inspection readiness and response: 483 answers, corrective-action plans, warning-letter strategy
  5. Ongoing counsel as products, suppliers and regulations change — FDA compliance is maintained, not achieved

4. Common errors to avoid

  • Classifying products by marketing intuition instead of regulatory analysis of their claims
  • Assuming a co-packer’s or supplier’s registrations cover your obligations
  • Copying a competitor’s label and inheriting its violations
  • Answering a Form 483 or warning letter with promises instead of documented corrective actions
  • Building compliance for one product category while importing across five

Doral: the local picture

The work around Doral — import/export headquarters, freight forwarding, cosmetics and fragrance trade, food and beverage importers, medical and pharmaceutical distribution — is FDA-regulated at nearly every turn, and matters here move on the city built around MIA’s west side, home to more trade, logistics and import businesses than any other Miami-Dade municipality. Garg Law's Miami office is at 1221 Brickell Avenue, and the practice was built for exactly this market: founder Shelly Garg spent years counseling importers at the world's largest dedicated international trade law firm before opening her own, and works at the crossroads of FDA and CBP compliance for foreign and domestic companies across the food, beverage, supplement, cosmetics, OTC drug and medical device industries.

Frequently asked questions

What does an FDA compliance attorney actually do?

Everything between product concept and enforcement defense: classification opinions, registrations and listings, label and claims review, manufacturing and supplier compliance programs, import strategy, and responses to inspections, warning letters and recalls. The value is preventing the second half by doing the first half well.

How do I know which FDA rules apply to my product?

Classification drives everything, and claims drive classification — the same formulation can be a cosmetic or an unapproved drug depending on what the label promises. A classification analysis against the Food, Drug, and Cosmetic Act’s definitions is the first step for any new product.

What should I do when FDA shows up to inspect?

Cooperate professionally, document everything the investigator sees and takes, and involve counsel immediately — especially before responding to a Form 483. The response window is short and the response quality shapes whether the matter ends there or escalates to a warning letter.

Is a warning letter the end of the road?

No — it is FDA’s formal demand for correction, and a strong, evidence-backed response with completed corrective actions closes most of them. Ignored or answered weakly, warning letters escalate to import alerts, seizures, injunctions and consent decrees.

We import through Miami — does that change our compliance picture?

It concentrates it. Import-heavy operations face FDA at the border on every entry — screening, holds, detention risk — on top of the domestic rules. Entry data, registrations and supplier verification need to be airtight because they are tested shipment by shipment.

Related resources

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.